ECTRIMS highlights

Efficacy results
Monitoring and safety issues
Commentary by Dr. Paul S. Giacomini, Associate Director, MS Clinic, Montreal Neurological Hospital and Institute, Assistant Professor, Department of Neurology and Neurosurgery, McGill University

Natalizumab and alemtuzumab are the two high-efficacy monoclonal antibodies typically used to treat aggressive multiple sclerosis and patients with an inadequate response to prior therapies. New data on the use of these agents were presented at the 31^st congress of the European Committee for Treatment and Research in MS (ECTRIMS). The following summarizes some of the research addressing efficacy, mode of action and safety considerations. Read More

ECTRIMS highlights

Long-term data
Safety studies
Comment: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada

The 31^st congress of the European Committee for Treatment and Research in MS (ECTRIMS) featured new research on current therapies for multiple sclerosis. In Canada, two oral therapies – teriflunomide and dimethyl fumarate (DMF) – are routinely used as first-line agents. The following summarizes key data for these two therapies presented at ECTRIMS. Read More

European Committee for Treatment and Research in MS (ECTRIMS) 31^st Congress – Barcelona, Spain, October 7-10, 2015 – The Late Breaking session at ECTRIMS 2015 was especially interesting this year as new data were presented on several novel MS treatments. Read More